These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33571878)

  • 1. LDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Masson G; Lavalle-Cobo A; Molinero G
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105655. PubMed ID: 33571878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.
    Hsu HY; Lin CJ; Lee YS; Wu TH; Chien KL
    BMC Cardiovasc Disord; 2020 Jul; 20(1):334. PubMed ID: 32660417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis.
    Judge C; Ruttledge S; Costello M; Murphy R; Loughlin E; Alvarez-Iglesias A; Ferguson J; Gorey S; Nolan A; Canavan M; O'Halloran M; O'Donnell MJ
    J Stroke Cerebrovasc Dis; 2019 Jun; 28(6):1703-1709. PubMed ID: 30878368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm.
    Nastasi DR; Norman R; Moxon JV; Quigley F; Velu R; Jenkins J; Golledge J
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):643-650. PubMed ID: 34507892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
    Arnold SV; Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Alam S; Mues KE; Bhatt DL; Kosiborod M;
    J Am Heart Assoc; 2021 Aug; 10(16):e020893. PubMed ID: 34369165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.
    Hammoudeh AJ; Echtay A; Ghanem GY; Haddad J;
    Curr Med Res Opin; 2014 Oct; 30(10):1957-65. PubMed ID: 24889279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bétrisey S; Haller ML; Efthimiou O; Speierer A; Del Giovane C; Moutzouri E; Blum MR; Aujesky D; Rodondi N; Gencer B
    J Am Heart Assoc; 2024 Feb; 13(4):e030714. PubMed ID: 38323514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis.
    Masson W; Lobo M; Masson G; Molinero G; Casciato P
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1357-1364. PubMed ID: 33715945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.